Stefan Strobl

Planegg, BY 82152, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Cyclin-Dependent Kinases (CDKs) and the Human Cytomegalovirus-Encoded CDK Ortholog pUL97 Represent Highly Attractive Targets for Synergistic Drug Combinations.

Cyclin-Dependent Kinases (CDKs) and the Human Cytomegalovirus-Encoded CDK Ortholog pUL97 Represent Highly Attractive Targets for Synergistic Drug Combinations.

Journal: International journal of molecular sciences
Published: January 27, 2022

Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.

Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.

Journal: Oncoimmunology
Published: November 03, 2018

Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity.

Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity.

Journal: Antiviral research
Published: June 21, 2018

A new promising candidate to overcome drug resistant herpes simplex virus infections.

A new promising candidate to overcome drug resistant herpes simplex virus infections.

Journal: Antiviral research
Published: July 27, 2017

Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria.

Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria.

Journal: Nature communications
Published: April 07, 2017

Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity.

Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity.

Journal: Antiviral research
Published: December 15, 2016

SC83288 is a clinical development candidate for the treatment of severe malaria.

SC83288 is a clinical development candidate for the treatment of severe malaria.

Journal: Nature communications
Published: June 10, 2016

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Journal: Oncoimmunology
Published: January 08, 2016

A new small molecule for treating inflammation and chorioretinal neovascularization in relapsing-remitting and chronic experimental autoimmune uveitis.

A new small molecule for treating inflammation and chorioretinal neovascularization in relapsing-remitting and chronic experimental autoimmune uveitis.

Journal: Investigative ophthalmology & visual science
Published: December 18, 2014

RPPApipe: a pipeline for the analysis of reverse-phase protein array data.

RPPApipe: a pipeline for the analysis of reverse-phase protein array data.

Journal: Bio Systems
Published: March 21, 2014

Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis.

Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis.

Journal: Antiviral research
Published: July 07, 2013

Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK.

Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK.

Journal: Antiviral research
Published: December 12, 2012
Showing 1-12 of 16

Last Updated: 09/26/2026